RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

Fei Su, Amaya Viros, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis-Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noe, Maryou LambrosFelipe Geyer, Nathalie Dhomen, Ion Niculescu-Duvaz, Alfonso Zambon, Dan Niculescu-Duvaz, Natasha Preece, Lídia Robert, Nicholas J. Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, Keith B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, Rene Gonzalez, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas*, Richard Marais

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

923 Scopus citations

Fingerprint

Dive into the research topics of 'RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology